Procept Biorobotics :: Advancing Minimally Invasive Urologic Robotics

Procept Biorobotics: Advancing Minimally Invasive Urologic Robotics

Company Overview

Procept Biorobotics is a commercial-stage medical technology company transforming urologic surgical care through robotically controlled, heat-free interventions. Founded in 2009 and headquartered in Toronto, Ontario, Canada, the company listed on the NASDAQ Global Market in 2021 under the ticker PRCX. Its core focus is addressing unmet needs in benign prostatic hyperplasia (BPH) treatment: a condition affecting millions of aging men, where traditional surgical options often carry high risks of long-term sexual dysfunction or urinary incontinence.
Core Technology

The company’s proprietary Aquablation therapy uses a high-velocity, robotically guided waterjet to precisely remove obstructive prostate tissue without applying thermal energy to surrounding structures. Unlike traditional transurethral resection of the prostate (TURP) or laser-based procedures, Aquablation avoids damage to the neurovascular bundles and urinary sphincter, preserving critical sexual and continence function. The system uses real-time ultrasound mapping and sub-millimeter robotic accuracy to execute surgeon-defined ablation plans.
Product Portfolio

The flagship AQUABEAM Robotic System is a fully integrated surgical platform with three core components:

A surgeon-controlled planning console
A high-pressure waterjet delivery module
A real-time transrectal ultrasound imaging system

It supports treatment of prostates from 30 to 150 grams, covering most surgical BPH cases, and requires no specialized facility retrofits for standard operating rooms.
Regulatory and Clinical Validation

The AQUABEAM system holds FDA clearance (U.S.), CE Mark approval (EU), and regulatory authorization in Canada, Australia, and key Asian markets. Clinical data shows Aquablation delivers equivalent BPH symptom relief to TURP, with a 3x lower risk of postoperative erectile dysfunction and 5x lower risk of urinary incontinence. 95% of patients retain sexual function 12 months post-procedure.
Global Adoption and Partnerships

As of 2025, Procept has deployed over 400 AQUABEAM systems across 20+ countries, with partnerships with major U.S. group purchasing organizations (GPOs) to expand adoption in community hospitals. Over 10,000 Aquablation procedures have been performed globally.
Future Roadmap

Procept is conducting clinical trials to expand Aquablation to treat larger prostates (up to 200 grams) and is exploring its robotic waterjet technology for kidney stone fragmentation and bladder tumor removal. The company targets 150+ new system placements annually by 2027, aiming to make Aquablation the first-line surgical BPH treatment worldwide.